Focused On-demand Library for Proteasome maturation protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9Y244

UPID:

POMP_HUMAN

Alternative names:

Proteassemblin; Protein UMP1 homolog; Voltage-gated K channel beta subunit 4.1

Alternative UPACC:

Q9Y244; A5HKJ2; D6MXU3; Q9HB69

Background:

The Proteasome maturation protein, also known as Proteassemblin, Protein UMP1 homolog, and Voltage-gated K channel beta subunit 4.1, plays a pivotal role in cellular function. It acts as a molecular chaperone essential for the assembly of standard proteasomes and immunoproteasomes, facilitating the association of 20S preproteasome with the endoplasmic reticulum. This protein is degraded after proteasome maturation is complete.

Therapeutic significance:

Linked to diseases such as Keratosis linearis with ichthyosis congenita and sclerosing keratoderma, and Proteasome-associated autoinflammatory syndrome 2, the Proteasome maturation protein's involvement in these conditions underscores its potential as a target for therapeutic intervention. Understanding its role could lead to novel treatments for these debilitating diseases.